跳至主要内容
临床试验/CTRI/2019/05/019359
CTRI/2019/05/019359尚未招募未知

Continuous Intravenous Infusion versus Intermittent Intramuscular Injection of Tramadol for Sickle Cell Vaso-occlusive Crisis: An Open Label Randomized Trial

VIMSAR0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1-diagnosed case of sickle cell disease with vaso-occlusive crisis both homozygous and compound hetrerozygous(by HPLC study)
  • 2-VOC will be diagnosed if the patient present with pain involving skeleton, chest, abdomen or all three lasting 4hours or more.
  • 3-moderate to severe grade of VOC (VISUAL ANALOGUE SCALE)

排除标准

  • 1- cases associated with diabetes mellitus, stroke, peripheral vascular disease, polycythemia that are likely to modify viscosity of blood.
  • 2- contraindication for tramadol.
  • 3- critically ill patients including acute chest syndrome.

研究者

发起方
VIMSAR

相似试验

Efficacy of Intravenous versus Intramuscular... | 临床试验